Introduction {#tca12774-sec-0005}
============

Statistical studies of cancer have revealed that breast cancer is one of the most common malignant carcinomas diagnosed and the seconding leading cause of cancer related‐death in women.[1](#tca12774-bib-0001){ref-type="ref"}, [2](#tca12774-bib-0002){ref-type="ref"}, [3](#tca12774-bib-0003){ref-type="ref"} Axillary lymph node metastasis is common in breast cancer patients, which also affects the treatment modality and surgical procedure.[4](#tca12774-bib-0004){ref-type="ref"} Axillary lymph node status of patients with breast cancer is usually assessed by sentinel lymph node biopsy (SLNB), core needle biopsy (CNB), or fine needle aspiration cytology (FNAC). However, these procedures are mini‐invasive and potentially lead to implantation metastasis. Magnetic resonance imaging (MRI), with high resolution of different tissues, is widely used to diagnose many types of cancers and also affects treatment modality. Previously studies have evaluated its performance for evaluating the axillary lymph node status of patients with breast cancer. However, because of the small sample sizes of previous studies, statistical research is limited. In our present study, we searched open published studies relevant to MRI for the detection of axillary lymph node metastasis in patients with breast cancer and conducted a meta‐analysis to further evaluate diagnostic performance.

Methods {#tca12774-sec-0006}
=======

Publication searching {#tca12774-sec-0007}
---------------------

PubMed, Medline, Web of Science, Cochrane Embase, Chinese Biomedical Literature, and China National Knowledge Infrastructure databases were searched for open published studies relevant to the use of MRI to detect axillary lymph node metastasis in patients with breast cancer. The search procedure is demonstrated in Figure [1](#tca12774-fig-0001){ref-type="fig"}. The terms "breast cancer" OR "breast carcinoma" OR "breast neoplasm" And "axillary lymph node" And "MRI" OR "magnetic resonance imaging" OR "MR" were used.

![Search procedure.](TCA-9-989-g004){#tca12774-fig-0001}

Study inclusion and exclusion {#tca12774-sec-0008}
-----------------------------

Two reviewers drew up the inclusion and exclusion criteria and crosschecked the data. The inclusion criteria were: (i) prospective or retrospective diagnostic studies; (ii) studies relevant to the evaluation of MRI to detect axillary lymph node metastasis in patients with breast cancer; (iii) the axillary lymph node metastasis was confirmed by pathological examination; and (iv) the number of true positive (TP), false positive (FP), false negative (FN), and true negative (TN) results could be extracted from each individual study. The exclusion criteria were: (i) duplicate publications or data; (ii) literature review of case reports; (iii) malignant carcinoma other than breast cancer; and (iv) diagnostic data could not be extracted from individual studies.

Initially, 268 relevant studies were identified. Nineteen duplicated publications or data were excluded. After reading the title and abstract, 204 studies were excluded. After review of the full text, a further 19 studies were excluded. Twenty‐six open published studies were finally included in the meta‐analysis (Fig [1](#tca12774-fig-0001){ref-type="fig"}). The main features of the included 26 studies are listed in Table [1](#tca12774-tbl-0001){ref-type="table"}.

###### 

General characteristics of the included publications

  First author                                               Year   Country       Study type      Reference standard   Lymph node   Age (year)   TP    FP   FN   TN
  ---------------------------------------------------------- ------ ------------- --------------- -------------------- ------------ ------------ ----- ---- ---- ------
  Chen[5](#tca12774-bib-0005){ref-type="ref"}                2014   China         NR              ALND/CNB             154          21--82       70    8    17   59
  Meng[6](#tca12774-bib-0006){ref-type="ref"}                2013   China         NR              SLNB                 35           35--61       10    0    1    24
  Wang[7](#tca12774-bib-0007){ref-type="ref"}                2013   China         Retrospective   ALND/SLNB            136          21--77       55    11   8    62
  Xie[8](#tca12774-bib-0008){ref-type="ref"}                 2014   China         Retrospective   ALND/SLNB            193          21--73       60    9    20   104
  Xu[9](#tca12774-bib-0009){ref-type="ref"}                  2004   China         NR              ALND                 17           34--70       9     2    2    4
  Yin[10](#tca12774-bib-0010){ref-type="ref"}                2013   China         NR              ALND                 268          NR           63    52   15   148
  Du[11](#tca12774-bib-0011){ref-type="ref"}                 2017   China         NR              ALND                 229          NR           91    17   11   110
  Harada[12](#tca12774-bib-0012){ref-type="ref"}             2007   Japan         Prospective     ALND                 506          36--77       42    73   23   368
  Kimura[13](#tca12774-bib-0013){ref-type="ref"}             2009   Japan         Prospective     ALND                 10           35--79       2     0    0    8
  Kvistad[14](#tca12774-bib-0014){ref-type="ref"}            2000   Norway        NR              ALND                 65           38--78       6     1    18   40
  Memarsadeghi[15](#tca12774-bib-0015){ref-type="ref"}       2006   Australia     Prospective     ALND                 22           40--79       6     23   5    99
  Michel[16](#tca12774-bib-0016){ref-type="ref"}             2002   Switzerland   Prospective     ALND                 18           22--76       25    9    5    243
  Mumtaz[17](#tca12774-bib-0017){ref-type="ref"}             1997   UK            NR              ALND                 75           29--80       21    5    5    64
  García Fernández[18](#tca12774-bib-0018){ref-type="ref"}   2011   Spain         Prospective     ALND                 105          52.5         14    3    25   63
  Hwang[19](#tca12774-bib-0019){ref-type="ref"}              2013   Korea         Prospective     ALND/SLNB            349          25--79       44    29   48   228
  Javid[20](#tca12774-bib-0020){ref-type="ref"}              2010   USA           Prospective     ALND                 47           NR           24    2    4    17
  Chung[21](#tca12774-bib-0021){ref-type="ref"}              2013   USA           Prospective     ALND                 110          NR           68    7    0    35
  Fornasa[22](#tca12774-bib-0022){ref-type="ref"}            2012   Italy         Prospective     ALND                 43           NR           18    2    1    22
  Rautiainen[23](#tca12774-bib-0023){ref-type="ref"}         2015   Finland       Prospective     ALND                 32           28--82       22    0    3    7
  He[24](#tca12774-bib-0024){ref-type="ref"}                 2012   China         Retrospective   ALND                 1242         NR           108   26   34   1074
  Kamitani[25](#tca12774-bib-0025){ref-type="ref"}           2013   Japan         Retrospective   ALND                 110          25--81       24    47   2    37
  Kim[26](#tca12774-bib-0026){ref-type="ref"}                2014   Korea         NR              ALND                 253          28--82       69    26   22   136
  Li[27](#tca12774-bib-0027){ref-type="ref"}                 2014   China         Prospective     SLNB                 121          30--58       53    1    3    64
  Luo[28](#tca12774-bib-0028){ref-type="ref"}                2013   China         NR              ALND                 78           30--63       38    4    7    30
  Motomura[29](#tca12774-bib-0029){ref-type="ref"}           2011   Japan         Prospective     SLNB                 102          57           21    7    4    70
  Nakai[30](#tca12774-bib-0030){ref-type="ref"}              2011   Japan         Prospective     ALND                 216          36--77       30    4    6    176

ALND, axillary lymph node dissection; FN, false negative; FP, false positive; NR, not reported; SLNB, sentinel lymph node biopsy; TN, true negative; TP, true positive.

Data extraction {#tca12774-sec-0009}
---------------

Two reviewers independently reviewed the data of each included study. General information, such as sample size, year of publication, diagnostic gold standard, and patient age, were extracted. The number of TP, FP, FN, and TN results were carefully extracted from each study and crosschecked.

Statistical methods {#tca12774-sec-0010}
-------------------

All analysis was performed using MetaDiSc 1.4 software (<http://www.hrc.es/investigacion/metadisc_en.htm>). Statistical heterogeneity across the 26 included studies was assessed by I^2^ test. The data was pooled by fixed or random effect method according to the heterogeneity. Publication bias was assessed by line regression test. Diagnostic sensitivity and specificity was calculated using the formula: sensitivity = TP/(TP + FN) and specificity = TN/(TN + FP). *P* \< 0.05 was considered statistically significant.

Results {#tca12774-sec-0011}
=======

Sensitivity and specificity analysis {#tca12774-sec-0012}
------------------------------------

The diagnostic sensitivity and specificity of MRI to detect axillary lymph node metastasis in patients with breast cancer were pooled by random effect method because of significant statistical heterogeneity (I^2^ = 86.6% for sensitivity; I^2^ = 92.5% for specificity). The pooled sensitivity and specificity were 0.77 (95% confidence interval \[CI\] 0.75--0.80) (Fig [2](#tca12774-fig-0002){ref-type="fig"}) and 0.90 (95% CI 0.89--0.91) (Fig [3](#tca12774-fig-0003){ref-type="fig"}), respectively.

![Forest plot of pooled diagnostic sensitivity. CI, confidence interval.](TCA-9-989-g003){#tca12774-fig-0002}

![Forest plot of pooled diagnostic specificity. CI, confidence interval.](TCA-9-989-g001){#tca12774-fig-0003}

Positive and negative likelihood ratios {#tca12774-sec-0013}
---------------------------------------

The pooled positive and negative likelihood ratios were 7.67 (95% CI 5.09--11.53) (Fig [4](#tca12774-fig-0004){ref-type="fig"}) and 0.23 (95% CI 0.17--0.32), respectively, by random effect method (Fig [5](#tca12774-fig-0005){ref-type="fig"}).

![Forest plot of pooled positive likelihood ratio (LR). CI, confidence interval.](TCA-9-989-g002){#tca12774-fig-0004}

![Forest plot of pooled negative likelihood ratio (LR). CI, confidence interval.](TCA-9-989-g007){#tca12774-fig-0005}

Diagnostic odds ratio {#tca12774-sec-0014}
---------------------

Because of significant heterogeneity across the included 26 studies (I^2^ = 80.9%; *P* \< 0.05), the diagnostic odds ratio (DOR) was pooled by random effect method. The pooled DOR was 36.69, with a 95% confidence interval of 22.09--60.92 (Fig [6](#tca12774-fig-0006){ref-type="fig"}).

![Forest plot of diagnostic odds ratio (OR). CI, confidence interval.](TCA-9-989-g008){#tca12774-fig-0006}

Symmetric receiver operating characteristic curve {#tca12774-sec-0015}
-------------------------------------------------

The symmetric receiver operating characteristic (SROC) curve was calculated by sensitivity against 1‐specificity using MetaDiSc 1.4 software. The area under the SROC curve (AUC) was 0.93 for MRI for the detection of axillary lymph node metastasis in breast cancer patients (Fig [7](#tca12774-fig-0007){ref-type="fig"}).

![Pooled symmetric receiver operating characteristic (SROC) curves. AUC, area under the curve; SE, standard error.](TCA-9-989-g006){#tca12774-fig-0007}

Evaluation of publication bias {#tca12774-sec-0016}
------------------------------

The studies were evaluated by line regression test and no significant publication bias was observed (t = 0.33; *P* \> 0.05) (Fig [8](#tca12774-fig-0008){ref-type="fig"}).

![Egger\'s line regression test to evaluate publication bias.](TCA-9-989-g005){#tca12774-fig-0008}

Discussion {#tca12774-sec-0017}
==========

Recent studies have shown that breast cancer has become one of the leading causes of cancer‐related death worldwide. It is estimated that 266 120 new breast cancer patients will be diagnosed in the United States in 2018.[31](#tca12774-bib-0031){ref-type="ref"} Breast cancer is the most commonly diagnosed malignant carcinoma in women. Fortunately, the long‐term (five‐year) survival rate of breast cancer in women is approximately 90%.

As described in previous studies, axillary lymph node involvement is one the key factors relevant to prognosis in breast cancer patients. A clear understanding of the status of axillary lymph nodes in breast cancer patients is important not only for prognosis but also to select treatment modality or surgical method. Axillary lymph node dissection (ALND) is the reference standard for evaluating lymph node involvement. However, approximately 40--70% of breast cancer patients have histopathologically negative axillary lymph nodes[32](#tca12774-bib-0032){ref-type="ref"} indicating that 40--70% of breast cancer patients undergo unnecessary invasive examinations. Determining axillary lymph node involvement before treatment or dissection is important to reduce such examinations.

The diagnostic performance of MRI to detect axillary lymph node metastasis in patients with breast cancer has been widely discussed. However, the exact diagnostic performance of MRI for discriminating axillary lymph node involvement is not fully understood because of the inconsistent results reported by previous studies.[25](#tca12774-bib-0025){ref-type="ref"}, [26](#tca12774-bib-0026){ref-type="ref"}, [28](#tca12774-bib-0028){ref-type="ref"} These inconsistencies may be the result of: (i) small sample sizes with limited statistical power; (ii) patient inclusion criteria; (iii) MRI examination technology; (iv) types of MRI instruments used; and (v) different reference standards for axillary lymph node involvement.

In our present study, we included 26 studies that evaluated the diagnostic performance of MRI to determine axillary lymph node involvement in breast cancer and pooled the diagnostic sensitivity (0.77, 95% CI 0.75--0.80), specificity (0.90, 95% CI 0.89--0.91), and SROC (0.92) to further assess its value in clinical application. However, there are some limitations to our meta‐analysis. Firstly, we only searched for studies published in English or Chinese, which may have led to publication selection bias. Secondly, significant statistical heterogeneity existed in the sensitivity, specificity, positive and negative likelihood ratios, and ROC effect sizes. Thirdly, not all of the included studies were prospective, reducing the reliability of our results.

Our results show that MRI is an effective method for differentiating metastatic axillary lymph nodes in breast cancer patients because of high sensitivity, specificity, and AUC, and thus can provide useful information for surgical procedure selection.
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